MARKET

RETA

RETA

Reata Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

111.10
+1.10
+1.00%
After Hours: 109.80 -1.3 -1.17% 16:00 01/21 EST
OPEN
111.00
PREV CLOSE
110.00
HIGH
111.96
LOW
106.83
VOLUME
212.73K
TURNOVER
--
52 WEEK HIGH
257.97
52 WEEK LOW
88.17
MARKET CAP
4.01B
P/E (TTM)
-9.7853
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Diabetic Nephropathy Market Size, Share, Growth, Trends and Upcoming Opportunities In 2020 – 2024
Jan 20, 2021 (AmericaNewsHour) -- Global Diabetic Nephropathy Market is estimated to reach $3,826 million by 2024; growing at a CAGR of 5.9% from 2016 to...
AmericaNewsHour · 1d ago
Citing uncertainty, Baird stays neutral on Biotech for 2021
Heading into 2021, Baird keeps a neutral view on Biotechnology despite higher expectations after the sector with a 26% gain in the iShares Nasdaq Biotechnology ETF (IBB) outperformed in 2020
Seekingalpha · 01/04 21:40
An Intrinsic Calculation For Reata Pharmaceuticals, Inc. (NASDAQ:RETA) Suggests It's 50% Undervalued
Simply Wall St. · 12/21/2020 12:55
The Daily Biotech Pulse: Pfizer-BioNTech Vaccine Gets Temporary UK Authorization, Ovid's Trial Disappointment, Vanda Snags FDA Nod
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 1)
Benzinga · 12/02/2020 12:35
Reata Pharmaceuticals under pressure on pricing equity offering
Reata Pharmaceuticals (RETA) has priced 2M Class A common stock at $140.85/share, for gross proceeds of $281.7M.Underwriters' over-allotment is an additional 300K Class A common stock.Offering is expected to close
Seekingalpha · 12/02/2020 10:01
Reata Pharmaceuticals, Inc. Announces Pricing of Class A Common Stock Offering
PLANO, Texas, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced that it has priced a public offering of 2,000,000 shares by the Company of its Class A common stock at a price to the public of $140.85 per share, for gross proceeds of $281.7 million. Reata has granted the underwriters a 30-day option to purchase 300,000 additional shares of its Class A common stock, on the same terms and conditions as the shares offered in the public offering. The offering is expected to close on or about December 4, 2020, subject to customary closing conditions. Barclays Capital Inc. and Goldman Sachs & Co. LLC are acting as joint book-running managers.The securities described above are being offered pursuant to an effective shelf registration statement on Form S-3. The offering may be made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A final prospectus supplement and accompanying prospectus relating to the offering will be filed with the Securities and Exchange Commission (the “SEC”) and will be available on the SEC’s website at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus, when available, may also be obtained by request at Barclays Capital Inc., Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, telephone: 1-888-603-5847, or by emailing Barclaysprospectus@broadridge.com; or Goldman Sachs & Co. LLC, Prospectus Department, 200 West Street, New York, NY 10282, telephone: 1-866-471-2526, facsimile: 212-902-9316 or by emailing Prospectus-ny@ny.email.gs.com.This news release is for informational purposes only and shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities, in any state or jurisdiction in which such offer, solicitation or sale of these securities would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.About Reata Pharmaceuticals, Inc.Reata is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. Reata’s two most advanced clinical candidates, bardoxolone methyl (“bardoxolone”) and omaveloxolone, target the important transcription factor Nrf2 that promotes restoration of mitochondrial function, reduction of oxidative stress, and inhibition of pro-inflammatory signaling. Bardoxolone and omaveloxolone are investigational drugs, and their safety and efficacy have not been established by any agency.Forward-Looking StatementsThis press release includes certain disclosures that contain “forward-looking statements,” including, without limitation, statements regarding the public offering and the anticipated use of proceeds of the offering, the success, cost and timing of our product development activities and clinical trials, our plans to research, develop and commercialize our product candidates, our plans to submit regulatory filings, and our ability to obtain and retain regulatory approval of our product candidates. You can identify forward-looking statements because they contain words such as “believes,” “will,” “may,” “aims,” “plans,” “model,” and “expects.” Forward-looking statements are based on Reata’s current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, (i) the uncertainties related to market conditions and the completion of the public offering on the anticipated terms or at all; (ii) the timing, costs, conduct, and outcome of our clinical trials and future preclinical studies and clinical trials, including the timing of the initiation and availability of data from such trials; (iii) the timing and likelihood of regulatory filings and approvals for our product candidates; (iv) whether regulatory authorities determine that additional trials or data are necessary in order to obtain approval; (v) the potential market size and the size of the patient populations for our product candidates, if approved for commercial use, and the market opportunities for our product candidates; and (vi) other factors set forth in Reata’s filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2019 and Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, under the caption “Risk Factors.” The forward-looking statements speak only as of the date made and, other than as required by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.Contact: Reata Pharmaceuticals, Inc. (972) 865-2219Investor Relations: Vinny Jindal (469) 374-8721 ir@reatapharma.com
GlobeNewswire · 12/02/2020 02:48
TG, OVID, FCEL and MESO among after-hours movers
Gainers: [[TG]] +29.6%. [[MESO]] +11.8%. [[FUBO]] +10.5%. [[VAPO]] +9.2%. [[SLQT]] +6.5%.Losers: [[OVID]] -48.7%. [[FCEL]] -16.8%. [[IRTC]] -16.1%. [[SOL]] -13.2%. [[RETA]] -9.1%.
Seekingalpha · 12/01/2020 23:01
Reata Pharma launches 2M-share stock offering
Reata Pharmaceuticals (RETA) commences a public offering of 2M shares of common stock. Price and terms have yet to be announced.
Seekingalpha · 12/01/2020 21:16
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of RETA. Analyze the recent business situations of Reata Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average RETA stock price target is 246.75 with a high estimate of 320.00 and a low estimate of 212.00.
EPS
Institutional Holdings
Institutions: 306
Institutional Holdings: 24.43M
% Owned: 67.65%
Shares Outstanding: 36.12M
TypeInstitutionsShares
Increased
69
1.87M
New
72
-1.44M
Decreased
66
1.44M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.04%
Pharmaceuticals & Medical Research
-0.53%
Key Executives
Chairman/President/Chief Executive Officer/Director
J. Warren Huff
Chief Financial Officer/Chief Operating Officer/Executive Vice President
Manmeet Soni
Executive Vice President
Dawn Bir
Executive Vice President
Colin Meyer
Executive Vice President
Michael Wortley
Chief Technology Officer/Vice President
Kevin Johnston
Vice President
Andrea Loewen
Other
Seemi Khan
Independent Director
Martin Edwards
Independent Director
William McClellan
Independent Director
R. Kent McGaughy
Independent Director
Jack Nielsen
Independent Director
William Rose
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About RETA
Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases. The Company's lead product candidates include bardoxolone methyl, which is being studied in Phase III trial for the treatment of pulmonary arterial hypertension (PAH), associated with connective tissue disease (CTD-PAH), as well as a Phase II trial for the treatment of pulmonary hypertension due to interstitial lung disease (PH-ILD), and PAH, each of which are subsets of pulmonary hypertension (PH), Omaveloxolone, which is in Phase II clinical development for the treatment of multiple diseases, including Friedreich's ataxia, mitochondrial myopathies and metastatic melanoma.
More

Webull offers kinds of Reata Pharmaceuticals Inc stock information, including NASDAQ:RETA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RETA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RETA stock methods without spending real money on the virtual paper trading platform.